0 results for 'Eli Lilly'
Despite Call for Civility, 'Squabbles Among Counsel' Emerge Over Ozempic Leadership
Plaintiffs lawyers in the Ozempic multidistrict litigation organized a leadership team of 30 attorneys, but one Florida attorney objected to the proposed slate, which she says appears to be composed of 'repeat players.'TV Legal Ads Proving Useful Radar for Next Big Mass Tort Categories
Tracking television legal ads that solicit plaintiffs for mass torts can give general counsel early warning of new trends and gauge the plaintiffs' bar's appetite in product litigation categories.Despite Cuts, Fenwick Sees Revenue Growth and Remains Bullish on Tech Business Bounceback
"Some uncertainty remains. But it will come back, and come back stronger," said firm chair Richard Dickson about the firm's scope of work. "We just don't know exactly when."Social Media Ads Inject New Angle in Ozempic Cases: 'It's Going to Be a Huge Focus'
The proliferation of advertising on social media for Ozempic and related drugs will be a key part of the lawsuits against Novo Nordisk and Eli Lilly.View more book results for the query "Eli Lilly"
Don't Be Cranky and Don't Cause Delays: Judge Pushes for Efficiency in Ozempic MDL
"What I want is to avoid asking for continuances and asking for delay and asking for new dates. Just pick your poison and stick with it," Pratter told the approximately 70 people gathered in her courtroom Thursday.Weight-Loss-Drug Craze Pumps Up Pay for Lilly GC
Anat Hakim joined Lilly in 2020, just before the company's stock began a long ascent that has more than quadrupled its value—pushing the company's market capitalization past Tesla's.Elanco Hires GC Just as Activist Investor Calls for CEO's Ouster
Shiv O'Neill's first high-stakes task will be helping the company navigate its relationship with Ancora Capital.Finnegan, Recovering From Earlier Revenue Losses, Sees 6% Top-Line Growth
The firm has been investing in "adjacent services" that complement its traditional core IP offerings, said managing partner Erika Arner.Treatment of Antibody Claims In the U.S. After 'Amgen v. Sanofi'
The future of antibody claiming in the United States is uncertain following the U.S. Supreme Court's ruling in 'Amgen Inc. v. Sanofi,' a highly anticipated decision concerning enablement and whether the traditional way to claim antibodies — claiming antibodies by their function — will survive as a valid claiming strategy.Trending Stories
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250
Strong & Hanni Solves Storage Woes--Learn How You Can, Too
Brought to you by Filevine
Download Now
Meeting the Requirements of California's SB 553: Workplace Violence Prevention
Brought to you by NAVEX Global
Download Now
The Benefits of Outsourcing Beneficial Ownership Information Filing
Brought to you by Wolters Kluwer
Download Now
The Top 10 AI Use Cases in Private Equity
Brought to you by Ontra
Download Now